Necrolytic acral erythema is a distinct erythema that has been described as an extrahepatic manifestation of hepatitis C virus infection. Most reported cases have been in Africa, especially Egypt. We report the first case (to the best of our knowledge) of necrolytic acral erythema in a Chinese patient with HCV and HBV coinfection. We aim to increase awareness for recognizing this condition in the Chinese population.
INTRODUCTION
Necrolytic acral erythema (NAE) is a distinct form of necrolytic erythema that has been reported as a cutaneous marker for hepatitis C virus (HCV) infection. NAE was first described in 1996 in a series of seven patients with HCV infection in Egypt, and since then numerous cases of necrolytic acral erythema have been reported worldwide, mostly in Africa, especially Egypt. 1 To the best of our knowledge, we report the first case in the English and Chinese literature of necrolytic acral erythema in a mainland Chinese patient with HCV and hepatitis B virus (HBV) coinfection. 
CASE REPORT

DISCUSSION
An estimated 3% of the world's population is HCV-infected, with the highest prevalence in Egypt (15% to 20%), where the majority of cases with NAE have been reported. 2 In China, an updated national survey in 2006 showed that the anti-HCV prevalence rate was 0.43% in the general population, but NAE prevalence among HCV-positive patients remains undetermined. 3 Necrolytic acral erythema is one of the necrolytic erythemas, which include necrolytic migratory erythema (NME), acrodermatitis enteropathica, and various dermopathies secondary to nutritional deficiencies. NAE is distinct from the other necrolytic erythemas by virtue of its consistent association with hepatitis C (HCV) together with the acral distribution of its lesions. 4 Acute lesions of NAE present as erythematous papules and blisters that eventually lead to dark red erosions with a characteristic acral distribution. As for established lesions, sharply defined hyperkeratotic erythematous to violaceous plaques develop, and crusts may be seen. 5 Patients may report associated itching, burning, or aching pain in the lesions. 
